The global exosomes market was valued at USD 112.3 million in 2022 and it is predicted to surpass around USD 1,915.85 million by 2032 with a CAGR of 32.8% from 2023 to 2032.
Key Pointers
Report Scope of the Exosomes Market
Report Coverage | Details |
Market Size in 2022 | USD 112.3 million |
Revenue Forecast by 2032 | USD 1,915.85 million |
Growth rate from 2023 to 2032 | CAGR of 32.8% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Covered | Danaher Corporation; Hologic Inc.; Fujifilm Holdings Corporation; Lonza; Miltenyi Biotec; Bio-Techne Corporation; QIAGEN; Thermo Fisher Scientific, Inc.; Abcam plc; RoosterBio, Inc. |
Exosomes are also known as Extracellular Vesicles (EVs) and are encased within a single outer membrane. They are secreted by all cell types and have been found in saliva, urine, plasma, semen, breast milk, Cerebral Spinal Fluid (CSF), amniotic fluid, bronchial fluid, bile, lymph, serum, gastric acid, synovial fluid, and tears. These vesicles carry proteins and genetic information throughout the body and create paths for communication between cells.
The key factors driving the industry include technological advancements in exosome isolation and analytical procedures, advanced applications of exosomes, growth in government and non-government initiatives for exosome research, and the increasing prevalence of cancer. The COVID-19 pandemic led to the disruption of clinical trials investigating the diagnostic and therapeutic potential of exosomes in 2020. In addition, nationwide lockdown restrictions, disruption of supply chains, and diversion of investments toward COVID-19-related products led to a decrease in the research and development activities involving exosomes.
Despite the adverse impact in 2020, the pandemic has opened up several new prospects for the development of COVID-19 vaccines and treatments with the use of exosomes, which, in turn, is expected to boost industry growth over the coming years. For instance, in August 2022, researchers at the North Carolina State University developed an inhalable COVID-19 vaccine based on exosomes. Exosomes can also be used to determine the onset or progress of multiple diseases, including infectious diseases, neurodegenerative diseases, cancer, and Cardiovascular Diseases (CVDs), among others.
Moreover, the advantages of exosomes in drug delivery, such as biological barrier permeability, low immunogenicity and toxicity, and stability in circulation are increasing the therapeutics applications in this domain. Thus, the potential applications of extracellular vesicles in diagnostics, therapeutics, and vaccine development are projected to drive the industry over the forecast period. The growing prevalence of cancer is leading to a high demand for effective novel therapeutic options for the diagnosis and treatment of the disease. For instance, according to the World Health Organization (WHO), in 2020, there were about 10 million cancer deaths, making it one of the foremost causes of death worldwide.
Moreover, in the U.S., according to the American Cancer Society, an estimated 1,918,030 new cancer cases and 609,360 cancer deaths were recorded by the end of 2022. Furthermore, technological advancements in exosome isolation and analytical procedures are anticipated to boost industry growth during the forecast years. For instance, in November 2022, Cell Guidance Systems introduced its Instant Exosomes and LipoQ assay products. The Instant Exosomes are freeze-dried exosomes and LipoQ is a lipid quantification assay for research applications. Such, developments are expected to boost the adoption of exosomes for research purposes and drive industry growth.
Exosomes Market Segmentations:
By Product
By Workflow
By Application
By End-use
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Exosomes Market
5.1. COVID-19 Landscape: Exosomes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Exosomes Market, By Product
8.1. Exosomes Market, by Product, 2023-2032
8.1.1. Kits & Reagents
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Exosomes Market, By Workflow
9.1. Exosomes Market, by Workflow, 2023-2032
9.1.1. Isolation Methods
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Downstream Analysis
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Exosomes Market, By Application
10.1. Exosomes Market, by Application, 2023-2032
10.1.1. Cancer
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Neurodegenerative diseases
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cardiovascular diseases
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Infectious diseases
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Exosomes Market, By End-use
11.1. Exosomes Market, by End-use, 2023-2032
11.1.1. Pharmaceutical & biotechnology companies
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Hospitals & diagnostics centers
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Academic & research institutes
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Exosomes Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.1.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.4. Market Revenue and Forecast, by End-use (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-use (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Workflow (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-use (2020-2032)
Chapter 13. Company Profiles
13.1. Danaher Corporation
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Hologic Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Fujifilm Holdings Corporation
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Lonza
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Miltenyi Biotec
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bio-Techne Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. QIAGEN
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Thermo Fisher Scientific, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Abcam plc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. RoosterBio, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms